Synapse - Naiyer Rizvi

Search Within

Naiyer A Rizvi

Results (166)

Phase 3, randomized trial (CheckMate 017) of nivolumab (nivo) vs docetaxel in advanced squamous (SQ) cell non-small cell lung cancer (NSCLC)

Meeting Abstract

Rechamp, K.; Spigel, D. R.; Rizvi, N.; Poddubskaya, E.; West, H.; Eberhardt, W.; Baas, P.; Antonia, S. J.; Pluzanski, A.; Vokes, E. E.; more...
Asia-Pacific Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Longer-term follow-up of a phase 2 study (Checkmate 063) of nivolumab in patients with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC)

Meeting Abstract

Horn, L.; Rizvi, N.; Mazieres, J.; Planchard, D.; Stinchcombe, T. E.; Dy, G. K.; Antonia, S. J.; Lena, H.; Minenza, E.; Mennecier, B.; more...
Asia-Pacific Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Journal Article

Borghaei, H.; Paz-Ares, L.; Horn, L.; Spigel, D. R.; Steins, M.; Ready, N. E.; Chow, L. Q.; Vokes, E. E.; Felip, E.; Holgado, E.; more...
New England Journal of Medicine (2015)

Fulltext@MSK | Save

Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC)

Meeting Abstract

Hellmann, M. D.; Rizvi, N.; Gettinger, S. N.; Goldman, J.; Chow, L. Q.; Juergens, R.; Borghaei, H.; Brahmer, J.; Shen, Y.; Harbison, C. T.; more...
European Journal of Cancer (2015)

Fulltext@MSK | Save

First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses

Meeting Abstract

Gettinger, S. N.; Hellmann, M. D.; Shepherd, F. A.; Antonia, S. J.; Brahmer, J.; Chow, L. Q.; Goldman, J.; Juergens, R.; Borghaei, H.; Ready, N. E.; more...
European Journal of Cancer (2015)

Fulltext@MSK | Save

Preliminary safety, pharmacokinetics, and efficacy of regorafenib, cisplatin, and pemetrexed in patients with advanced nonsquamous non-small-cell lung cancers

Journal Article

Hellmann, M. D.; Sturm, I.; Trnkova, Z. J.; Lettieri, J.; Diefenbach, K.; Rizvi, N. A.; Gettinger, S. N.
Clinical Lung Cancer (2015)

Fulltext@MSK | Save

Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches

Journal Article

Drilon, A.; Wang, L.; Arcila, M. E.; Balasubramanian, S.; Greenbowe, J. R.; Ross, J. S.; Stephens, P.; Lipson, D.; Miller, V. A.; Kris, M. G.; more...
Clinical Cancer Research (2015)

Fulltext@MSK | Save

Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1-selected patients with non-small cell lung cancer (NSCLC)

Meeting Abstract

Spigel, D. R.; Chaft, J. E.; Gettinger, S. N.; Chao, B. H.; Dirix, L. Y.; Schmid, P.; Chow, L. Q. M.; Chappey, C.; Kowanetz, M.; Sandler, A.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC)

Meeting Abstract

Spigel, D. R.; Reckamp, K. L.; Rizvi, N. A.; Poddubskaya, E.; West, H. J.; Eberhardt, W. E. E.; Baas, P.; Antonia, S. J.; Pluzanski, A.; Vokes, E. E.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Incidence and management of interstitial lung disease in patients with advanced cancer treated with anti-programmed death receptor 1 ligand pembrolizumab

Meeting Abstract

Albano, M.; Gordon, R. A.; Rizvi, N. A.; Wolchok, J. D.
Oncology Nursing Forum (2015)

Fulltext@MSK | Save